

## **SAXENDA® REMS: Risk Evaluation and Mitigation Strategy**

A REMS (Risk Evaluation and Mitigation Strategy) is a strategy required by the Food and Drug Administration (FDA) to manage known or potential serious risks associated with a drug product to ensure the benefits of a drug outweigh its risks.

The purpose of the SAXENDA REMS is to inform healthcare providers of the following serious risks associated with SAXENDA:

- **Potential Risk of Medullary Thyroid Carcinoma**
- **Risk of Acute Pancreatitis**



**Please see Important Safety Information in this presentation.  
Please see Prescribing Information.**

**Saxenda®**  
(liraglutide) injection

# Potential Risk of Medullary Thyroid Carcinoma

## **BOXED WARNING: RISK OF THYROID C-CELL TUMORS**

- Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.
- It is unknown whether SAXENDA® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined.

## Potential Risk of Medullary Thyroid Carcinoma (2)

### Appropriate Patient Selection

- SAXENDA® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).

### Patient Management

- **Counsel patients** regarding the potential risk of MTC with the use of Saxenda and inform them of symptoms of thyroid tumors (e.g., **mass in the neck, dysphagia, dyspnea, persistent hoarseness**).
- **Instruct patients** to contact their healthcare provider promptly if these symptoms occur.
- Patients with thyroid nodules noted on physical examination or neck imaging should be further evaluated.

## Potential Risk of Medullary Thyroid Carcinoma (3)

### **Patient Management**

- Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value in patients treated with SAXENDA<sup>®</sup>. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated.

## Risk of Acute Pancreatitis

- Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide.
- In clinical trials studying SAXENDA<sup>®</sup>, there were more cases of pancreatitis in patients treated with SAXENDA<sup>®</sup> than in patients treated with placebo.

## Risk of Acute Pancreatitis (2)

### Appropriate Patient Selection

- SAXENDA® has not been studied sufficiently in patients with a history of pancreatitis.

### Patient Management

- After initiation of SAXENDA®, and after dose increases, **observe patients** carefully for signs and symptoms of pancreatitis.
- Counsel patients to contact their healthcare provider promptly if they experience symptoms of pancreatitis (including **persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting**).
- Discontinue promptly if pancreatitis is suspected.
- Do not restart if pancreatitis is confirmed.

Please see Important Safety Information in this presentation.  
Please see Prescribing Information.



**Saxenda**®  
(liraglutide) injection



Saxenda® is a registered trademark of Novo Nordisk A/S.  
Novo Nordisk is a registered trademark of Novo Nordisk A/S.  
© 2017 Novo Nordisk All rights reserved.

USA17SAM01966

June 2017

*Saxenda*®  
(liraglutide) injection